198 related articles for article (PubMed ID: 26083491)
1. ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.
Choueiri MB; Shen JP; Gross AM; Huang JK; Ideker T; Fanta P
PLoS One; 2015; 10(6):e0126898. PubMed ID: 26083491
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.
Shirota Y; Stoehlmacher J; Brabender J; Xiong YP; Uetake H; Danenberg KD; Groshen S; Tsao-Wei DD; Danenberg PV; Lenz HJ
J Clin Oncol; 2001 Dec; 19(23):4298-304. PubMed ID: 11731512
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
Kim SH; Kwon HC; Oh SY; Lee DM; Lee S; Lee JH; Roh MS; Kim DC; Park KJ; Choi HJ; Kim HJ
Am J Clin Oncol; 2009 Feb; 32(1):38-43. PubMed ID: 19194123
[TBL] [Abstract][Full Text] [Related]
5. Association between ERCC1 and TS mRNA levels and disease free survival in colorectal cancer patients receiving oxaliplatin and fluorouracil (5-FU) adjuvant chemotherapy.
Li S; Zhu L; Yao L; Xia L; Pan L
BMC Gastroenterol; 2014 Aug; 14():154. PubMed ID: 25175730
[TBL] [Abstract][Full Text] [Related]
6. Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis.
Kobayashi H; Sugihara K; Uetake H; Higuchi T; Yasuno M; Enomoto M; Iida S; Azuma M; Mori R; Omori A; Lenz HJ; Danenberg KD; Danenberg PV
Int J Oncol; 2008 Dec; 33(6):1257-62. PubMed ID: 19020759
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
Uchida K; Danenberg PV; Danenberg KD; Grem JL
BMC Cancer; 2008 Dec; 8():386. PubMed ID: 19105824
[TBL] [Abstract][Full Text] [Related]
8. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
[TBL] [Abstract][Full Text] [Related]
9. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
10. [Effect of TUBB3, TS and ERCC1 mRNA expression on chemoresponse and clinical outcome of advanced gastric cancer by multiplex branched-DNA liquid chip technology].
Huang J; Hu H; Xie Y; Tang Y; Liu W; Zhong M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jun; 38(6):582-9. PubMed ID: 23828702
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
Kwon HC; Roh MS; Oh SY; Kim SH; Kim MC; Kim JS; Kim HJ
Ann Oncol; 2007 Mar; 18(3):504-9. PubMed ID: 17322540
[TBL] [Abstract][Full Text] [Related]
12. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.
Grimminger PP; Shi M; Barrett C; Lebwohl D; Danenberg KD; Brabender J; Vigen CL; Danenberg PV; Winder T; Lenz HJ
Pharmacogenomics J; 2012 Oct; 12(5):404-11. PubMed ID: 21788964
[TBL] [Abstract][Full Text] [Related]
13. Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma.
Squires MH; Fisher SB; Fisher KE; Patel SH; Kooby DA; El-Rayes BF; Staley CA; Farris AB; Maithel SK
Cancer; 2013 Sep; 119(17):3242-50. PubMed ID: 23719746
[TBL] [Abstract][Full Text] [Related]
14. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.
Lee SH; Noh KB; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kim CH; Kang KH; In KH
Lung Cancer; 2013 Jul; 81(1):102-8. PubMed ID: 23523421
[TBL] [Abstract][Full Text] [Related]
15. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
[TBL] [Abstract][Full Text] [Related]
17. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
Niedzwiecki D; Hasson RM; Lenz HJ; Ye C; Redston M; Ogino S; Fuchs CS; Compton CC; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS; Bertagnolli MM
Oncologist; 2017 Jan; 22(1):107-114. PubMed ID: 27821793
[TBL] [Abstract][Full Text] [Related]
18. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
Jeong SH; Han JH; Kim JH; Ahn MS; Hwang YH; Lee HW; Kang SY; Park JS; Choi JH; Lee KJ; Sheen SS; Lim HY
Dig Dis Sci; 2011 Jan; 56(1):131-8. PubMed ID: 20503071
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer.
Noda E; Maeda K; Inoue T; Fukunaga S; Nagahara H; Shibutani M; Amano R; Nakata B; Tanaka H; Muguruma K; Yamada N; Yashiro M; Ohira M; Ishikawa T; Hirakawa K
Hepatogastroenterology; 2012; 59(113):130-3. PubMed ID: 21940361
[TBL] [Abstract][Full Text] [Related]
20. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
